On October 31, Bristol-Myers Squibb (NYSE: BMY ) released financial results for the third quarter of 2024 , which not only beat Wall Street analysts' expectations by a wide margin but also pleasantly surprised me.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceu ...

PHILADELPHIA, PENNSYLVANIA - NOVEMBER 07: Allyson McMillan-Youngblood, SVP U.S. Oncology, Bristol ... [+] Myers Squibb & Board Member, Pennsylvania Conference for Women speaks on stage during 2024 Pennsylvania Conference For Women at Pennsylvania Convention Center on November 07, 2024 in Philadelphia, Pennsylvania. (Photo by Marla Aufmuth/Getty Images for Pennsylvania Conference For Women )Getty Images for Pennsylvania Conference For WomenBristol Myers Squibb stock (NYSE: BMY) was up 10% on Monday, November ...

Key Points **Industry/Company Involved**: - Bristol-Myers Squibb Company (NYSE:BMY) **Core Points and Arguments**: - **Pipeline Strength and Portfolio Changes**: Bristol Myers Squibb has strengthened its pipeline with the addition of companies like Mirati, Karuna, and RayzeBio, expanding beyond immune-oncology. The company has also prioritized certain programs and removed others that were not meeting expectations. - **Research and Development (R&D) Productivity**: The company aims to increase the number of Investigational New Drug (IND) applications, reduce the time from IND approval to first indication approval, and increase the positive outcomes from INDs. - **COBENFY**: COBENFY, a treatment for schizophrenia, has shown promising results and is expected to have multiple indications over the next decade. The company is also exploring its potential in bipolar mania, Alzheimer's disease agitation, and other conditions. - **Milvexian**: Milvexian, a Factor 11 inhibitor, is in Phase III clinical trials for atrial fibrillation, acute coronary syndrome, and stroke prevention. The company remains confident in the drug's potential despite recent competitive challenges. - **CAR-T Therapy**: Bristol Myers Squibb is exploring the potential of CAR-T therapy in autoimmune diseases, including lupus and multiple sclerosis. The company has seen promising results in early trials and is actively researching other mechanisms for resetting immune memory. - **Immunology**: The company is developing a range of immunology assets, including Sotyktu, nivolumab, and relatlimab. The company is also exploring combinations of these drugs to improve outcomes for patients with various conditions. - **Multiple Myeloma**: Bristol Myers Squibb is taking a multi-modality approach to multiple myeloma, including small molecules, cell therapies, and combinations of these therapies. - **Hematology**: The company has a robust pipeline in hematology, including Golcadomide, mezigdomide, and BCL6 LDD. - **Cardiovascular Disease**: The company is developing MYK-224, a second cardiac myosin inhibitor, for the treatment of heart failure with preserved ejection fraction (HFpEF). - **Respiratory Diseases**: The company is developing LPA1, a treatment for idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PPF). **Other Important Points**: - **IRA Legislation**: The company expressed concerns about the potential impact of the IRA legislation on small molecule drugs and the potential for changes to the nine-year versus 13-year discussion. - **ASH Meeting**: The company is expected to present data on various assets at the upcoming ASH meeting, including Golcadomide, mezigdomide, GPRC5D, and BCL6 LDD. - **Future Data**: The company highlighted several data sets that it is excited about in the next 12 to 18 months, including milvexian, GPRC5D, COBENFY, SLE for Sjogren's, anti-TAL, FAAH and MAGLipase inhibitor, radioligand therapy in breast cancer and small cell lung cancer, GPC3 for radioligand therapy, and CCR8 in oncology.

Bristol Myers Squibb Company (BMY) touched a 52-week high of $56.8 on Nov. 6.  The stock is currently trading at $54.14. This biotech giant has been having a good run for the past three months, regaining its lost territories and giving anxious investors a ray of hope.Shares of BMY have risen 20.1% in the past six months compared with the industry’s growth of 5.3%. The stock has also outperformed the sector and the S&P 500 during this period.On Oct. 31, Bristol-Myers reported better-than-expected third-quart ...

The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve’s interest rate cuts in September. According to GlobalData, the top 20 global biopharmaceutical companies saw a 2% rise in their combined market capitalization, reaching $4.3 trillion by the end of September, up from $4.2 trillion in June. This rebound highlights the industry’s potential for growth despite challenges earlier in the year.Bristol-Myers Sq ...

29 August 2024, Bavaria, Munich: The logo of the pharmaceutical company Bristol-Myers Squibb, (BMS) ... [+] is seen on the facade of the company's Munich headquarters on August 29, 2024 in Munich (Bavaria). Photo: Matthias Balk/dpa (Photo by Matthias Balk/picture alliance via Getty Images)dpa/picture alliance via Getty ImagesBristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It reported revenue of $11.9 billion and adjusted earnings ...

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology stocks. But that means you may have overlooked two biopharmaceutical companies that delivered solid earnings reports.   Merck & Co. Inc. NYSE: MRK and The Bristol-Myers Squibb Co. NYSE: BMY beat analysts' estimates on the top and bottom lines. Revenue for both companies was higher than in the same quarter in 2023, but both companies reported lighter year-over-year earnings. For Bristol-Mye ...

Bristol-Myers Squibb Company (BMY) reported adjusted earnings per share (EPS) of $1.80 for the third quarter of 2024, which beat the Zacks Consensus Estimate of $1.49.  In the year-ago quarter, BMY had posted an adjusted EPS of $2.Total revenues of $11.9 billion surpassed the Zacks Consensus Estimate of $11.3 billion. The top line also increased 8% from the year-ago period’s level, primarily driven by a strong growth portfolio and an increase in Eliquis sales.BMY’s shares are trading up following the result ...

Bristol-Myers Squibb Company (NYSE:BMY) Q3 2024 Results Conference Call October 31, 2024 8:00 AM ET Company Participants Chuck Triano - Senior Vice President, Investor Relations Chris Boerner - Board Chair & Chief Executive Officer David Elkins - Chief Financial Officer Adam Lenkowsky - Chief Commercialization Officer Samit Hirawat - Chief Medical Officer & Head of Global Drug Development Conference Call Participants Evan Seigerman - BMO Capital Markets Chris Shibutani - Goldman Sachs Chris Schott - JPMorga ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-Q ___________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _______ Route 206 & Province Line Road, Princeton, New Jersey 08543 (Address of principal executive ...